Drug and Alcohol Dependence
September 1, 2026
S. Vanegas, J. Marusich, J. Maturano et al.
BACKGROUND AND PURPOSE Cannabinoids, including Δ9-tetrahydrocannabinol (THC) and synthetic CB1 agonists elicit acute psychotropic effects that undergo tolerance with repeated exposure. In contrast, the effects of prolonged cannabinol (CBN) use are unknown. This study examined (1) the effects of repeated CBN administration on classic cannabimimetic outcomes, (2) whether these effects undergo...
Psychopharmacology
September 1, 2026
Renée Martin-Willett, Samantha N. Melendez, Kent E. Hutchison et al.
RATIONALE An estimated two-thirds of medical cannabis users in the United States are motivated by chronic pain, but clinical guidance remains guarded as to whether the potential benefit of cannabinoids for pain outweighs potential risks, such as effects on cognition. OBJECTIVES In a study where participants experienced benefits of cannabinoids for pain and tension, we evaluated cannabis effects...
Perspectives on Science and Christian Faith
September 1, 2026
Yong Fang Zhu, Kyra White
With the legalization of cannabis and the proliferation of products containing its main psychoactive component, tetrahydrocannabinol (THC), the use of cannabis-associated psychoactive substances has moved from the margins to the mainstream and, in the case of recreational marijuana, involves products of increasing potency. This development raises several specific interdisciplinary questions,...
Current Neuropharmacology
August 31, 2026
Harrison J. Elder, Bryan W. Jenkins, C. Austin Zamarripa et al.
Introduction: This narrative review systematically examines the available empirical evidence for interactions between delta-9-tetrahydrocannabinol (Δ9-THC or THC) and C. sativa’s other phytochemical constituents hypothesized to underpin the popular yet controversial notion of ‘entourage effects’ experienced with botanical cannabis. Many relevant preclinical and clinical studies have been...
Neurochemical Research
August 27, 2026
Kazutoshi Yonemura, Nobue Kitanaka, Kazuo Tomita et al.
Cannabis, widely used for both medical and non-medical purposes, primarily contains Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). Δ9-THC is the main driver of cannabis abuse and of psychological and physical dependence, whereas CBD has limited abuse potential and is even being investigated as a treatment for cannabis use disorder and other conditions. This review aims to clarify how...
Nursing Edição Brasileira
August 27, 2026
O uso de Cannabis sativa tem crescido globalmente, acompanhado por um aumento significativo na concentração de delta-9-tetrahidrocanabinol (THC) nos produtos disponíveis no mercado. Esta revisão sistemática teve como objetivo analisar a associação entre a exposição a altas concentrações de THC, a precocidade no início do uso e o desenvolvimento de quadros psicóticos. A literatura demonstra uma...
Psychopharmacology
August 27, 2026
Frederick S. Barrett, David Wolinsky, Zach Daily et al.
RATIONALE: Delta-9-tetrahydrocannabinol (Δ9-THC) has been reported to evoke psychedelic-like experiences at high doses in some individuals. However, the doses of Δ9-THC that occasion such effects and the phenomenology of these experiences are poorly understood. OBJECTIVES: This brief report presents preliminary findings from a pilot human laboratory study that directly compared the acute...
Journal of Cannabis Research
August 26, 2026
Ario Safaeian, Kaylen M. Young, John G. Howland et al.
Abstract Background Cannabis use has increased in recent years due to legalization. Smoking cannabis leads to inhalation of ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in addition to other particles and gas in the smoke matrix as a result of combustion. The effect of THC on breathing pattern and metabolism has been characterized, but the influence of CBD and the smoke matrix on...
BJPsych Open
August 25, 2026
Edward Chesney, Millie Lloyd, Sébastien Brodeur et al.
BACKGROUND: Cannabis use is common in people with psychosis and is associated with poor outcomes. AIMS: To assess insight into cannabis use disorder, perceptions about how cannabis use influences mental health and the desire to change cannabis use among people with psychotic disorders. METHOD: Adults with a psychotic disorder and comorbid cannabis use disorder were asked about the impact of...
Neuropsychopharmacology
August 22, 2026
Carrie Cuttler, Matteya A Proctor, Nicholas C. Glodosky et al.
People who use cannabis commonly report stress-relieving effects, yet no studies have simultaneously assessed the acute effects of cannabis on multiple stress systems under placebo-controlled conditions. We conducted a randomized, double-blind, placebo-controlled trial in which 120 people (56 men, 52 women, 12 non-binary/transgender) who regularly use cannabis were assigned to vape placebo, a...
Molecular Neurobiology
August 20, 2026
Oleh Durydivka, Ondřej Florián, Petr Palivec et al.
Minor cannabinoids and semisynthetic cannabis constituents, such as derivatives of tetrahydrocannabinol (THC) and hexahydrocannabinol (HHC), are increasingly encountered in consumer products, yet their signaling profiles at cannabinoid receptors remain incompletely characterized. Here, we describe how structural modifications of THC and HHC, including variations in alkyl side-chain length...
Neuroscience & Biobehavioral Reviews
August 20, 2026
Lucy Chester, Heidar Sharafi, Amani Mahroug et al.
Research on the pharmacokinetic influence of cannabidiol (CBD) on delta-9-tetrahydrocannabinol (THC) has produced equivocal results. We conducted a systematic search following PRISMA guidelines (last search: 24th November 2025, PROSPERO: CRD42023480695). Included studies were acute dosing trials that administered a) a single, fixed dose of THC and b) a matched dose of THC co-administered with...
Frontiers in Psychiatry
August 17, 2026
Balázs Barko, Szabolcs Kéri
Introduction: Neuronal mechanisms of motion perception are susceptible to developmental anomalies. We tested whether heavy adolescent cannabis use is associated with enduring deficits in global motion perception, with relative sparing of global form perception, in abstinent adults. Methods: In a cross-sectional study, 130 adults were enrolled: cannabis-naïve controls (n=50), non-heavy...
Journal of addiction psychiatry
August 14, 2026
Sue D. Muggar, Jaime A. Perez, F. Laviolette et al.
Objectives: To utilize a retrospective observational design to characterize adolescents aged 13 - 17 presenting to emergency rooms (ER) in the United States (US) from 2016 to 2024 with psychosis and/or delta-9-tetrahydrocannabinol (THC) exposure via urine drug screens (UDS) and to evaluate trends in THC exposure, psychiatric comorbidities, and demographics. Material and Methods: De-identified,...
PLoS One
August 13, 2026
Paige Copeland, Quinn Malone, Brian H. Dalton et al.
The psychoactive component of cannabis, Δ9-tetrahydrocannabinol (THC), is known to alter cognitive-motor function; however, despite the high prevalence of cannabis use globally, the time course of the effects of ingesting THC is unclear. To allow future studies to accurately time the assessment of the impacts of cannabis on behaviour, this study aimed to establish a detailed time series of...
Psychology of Addictive Behaviors
August 13, 2026
Bridgid M Conn, Alisha Osornio, Kaia Sheean et al.
Despite increased naturalistic psychedelic use in the United States, limited studies explore factors currently contributing to use among ethnically and racially diverse psychedelic and cannabis-using adults. This study employs thematic analysis using qualitative data to explore the factors contributing to contemporary psychedelic use. Qualitative interviews (conducted in 2022-2023) from a...
Psychopharmacology
August 11, 2026
Madison Wright, Justin Matheson, Adam Zaweel et al.
RATIONALE Sex differences in the effects of cannabis have been demonstrated in animals, though the human evidence is more equivocal. In particular, more work is needed to better understand interactions between sex and dose in determining acute pharmacological effects of cannabis, especially at higher potencies of Δ9-tetrahydrocannabinol (THC). OBJECTIVES Sex differences were examined following...
Frontiers in Pharmacology
August 10, 2026
N. Miguel-Ramiro, N. Lamanna-Rama, M. Casquero-Veiga et al.
Background Disruptions in the gut-brain-microbiota axis are increasingly linked to psychiatric disorders. While cannabinoids possess immunomodulatory and neuroprotective properties, their impact on the microbial architecture during critical neurodevelopmental periods remains poorly understood. This exploratory study investigated whether adolescent treatment with delta-9-tetrahydrocannabinol...
Alcoholism & Drug Abuse Weekly
August 10, 2026
Alison Knopf
Cannabis use and cannabis use disorder (CUD) are common in early‐onset psychosis. Clinical presentation is key when determining which is present and which to treat first. But reducing cannabis use would help. A study published in the Journal of the American Academy of Child and Adolescent Psychiatry found that cannabis use preceded the psychosis symptoms. Researchers found that screening and...
Neurochemical Research
August 8, 2026
Duarte R Carvalhinho, Sandra I Marques, Sandra Leal et al.
The endocannabinoid system (ECS) plays a key role in regulating neurogenesis and inflammatory processes in the brain. The increasing prevalence of Cannabis use among women highlights the importance of understanding sex-specific effects of cannabinoids, particularly in the context of hormonal interactions. This study aimed to investigate the effects of delta-9-tetrahydrocannabinol (THC) and...